Literature DB >> 33642355

The effect of hepatic steatosis on COVID-19 severity: Chest computed tomography findings.

Selçuk Parlak1, Esra Çıvgın1, Muhammed Said Beşler1, Afşin Emre Kayıpmaz2.   

Abstract

Background: The objective of our study was to investigate the location, extension and type of novel coronavirus-induced disease 2019 (COVID-19) infection involvement and hepatic steatosis on initial chest computed tomography (CT). The relationship between fatty liver and severity of the disease was also investigated by measuring the liver attenuation index (LAI).
Methods: This study evaluated the chest CT images of 343 patients (201 male, mean age 48.43 years) who were confirmed to have COVID-19, using nasopharyngeal swab. The chest CTs were analyzed for laterality, number of involved lobes, diffuseness, number of lesions, and lesion types. The CT attenuation values of liver and spleen were measured, and LAI was calculated for the detection of hepatic steatosis. Univariate and multivariate logistic regression analysis were used to identify the independent early predictors for severe COVID-19.
Results: There was no significant difference between genders in terms of clinical course. Liver density and LAI were significantly lower in the intensive care unit (ICU) patients. The prevalence of severe disease was higher in the patients with hepatic steatosis than in the non-steatotic group (odds ratio [OR] 3.815, 95% confidence interval [CI] 1.97-7.37, P < 0.001). After adjusting for age and comorbidities including hypertension, diabetes mellitus, coronary artery disease, chronic obstructive pulmonary disease, and chronic kidney disease, multivariate logistic regression analysis showed that non-alcoholic fatty liver disease (NAFLD) was an independent risk factor for COVID-19 severity (OR 3.935, 95% CI 1.77-8.70, P = 0.001). The optimal cut-off value for LAI was calculated as 0.5 for predicting patients who required ICU treatment. Conclusions: On the initial chest CT images of COVID-19 patients, presence of fatty liver is a strong predictor for severe disease.

Entities:  

Keywords:  COVID-19; Computed tomography; hepatic steatosis; liver

Mesh:

Year:  2021        PMID: 33642355     DOI: 10.4103/sjg.sjg_540_20

Source DB:  PubMed          Journal:  Saudi J Gastroenterol        ISSN: 1319-3767            Impact factor:   2.485


  4 in total

Review 1.  Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Abraham Degarege; Zaeema Naveed; Josiane Kabayundo; David Brett-Major
Journal:  Pathogens       Date:  2022-05-10

2.  Hepatic steatosis: a risk factor for increased COVID-19 prevalence and severity-a computed tomography study.

Authors:  Asmaa Ali; Mona Hasan; Shaimaa Hamed; Amir Elhamy
Journal:  Egypt Liver J       Date:  2021-07-12

3.  Is Fatty Liver Associated with Increased Mortality and Morbidity in Coronavirus Disease 2019 (COVID-19) Pneumonia?

Authors:  Kaushal Madan; Ruchi Rastogi; Richa Bhargava; Vineeta Dagar; Vikas Singla; Amit Sahu; Pankaj Singh; Pallavi Garg; Bharat Aggarwal; Ramkrishna K Singh
Journal:  J Clin Exp Hepatol       Date:  2022-04-20

4.  The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Umar Hayat; Muhammad Zubair Ashfaq; Luke Johnson; Ryan Ford; Chelsea Wuthnow; Kevin Kadado; Katia El Jurdi; Hayrettin Okut; William Ransom Kilgore; Maha Assi; Ali A Siddiqui
Journal:  Kans J Med       Date:  2022-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.